MeiraGTx Holdings PLC (MGTX) Stock AnalysisMGTXMeiraGTx Holdings PLC

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

MeiraGTx Holdings PLC is currently trading at $9.28, significantly below the analyst price targets of $16 to $30, indicating potential upside. However, the stock has a low RSI of 26.123, suggesting it may be oversold, but the recent 5-day change of -13.19% raises concerns about short-term momentum. The company has shown strong revenue growth with a gross margin of 97.77% in Q2 2026, but the net income remains volatile with a recent EPS of 1.71, which was a significant surprise. The main risk is the forward P/E ratio of 64.1026, indicating high expectations for future earnings that may not materialize.

3 analysts cover MGTX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 21.50.